| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 3,681 | 2,765 | 1,502 | 3,779 |
| Cost of royalties | 5 | 39 | - | - |
| Research and development | 3,271 | 3,106 | 3,114 | 3,171 |
| General and administrative | 4,191 | 4,560 | 4,857 | 4,410 |
| Cost of sales | - | - | 36 | 38 |
| Loss on impairment of intangible asset (note 6 and note 13) | 0 | 14,840 | - | - |
| Total operating expenses | 7,467 | 22,545 | 8,007 | 7,619 |
| Loss from operations | -3,786 | -19,780 | -6,505 | -3,840 |
| Interest income, net | 366 | 454 | 478 | 397 |
| Gain (loss) on marketable equity securities, net | 6 | -2 | -5 | -6 |
| Change in fair value of warrant liability | 26,557 | 12,740 | -2,305 | - |
| Foreign currency transaction gain (loss), net | 219 | 1,678 | -231 | 448 |
| Other income (expense), net | 0 | 26 | -185 | - |
| Total other income (expenses) | -25,966 | -10,584 | 2,362 | 839 |
| Loss before income taxes | - | - | - | -3,001 |
| Net loss | -29,752 | -30,364 | -4,143 | -3,001 |
| Net (income) loss attributable to noncontrolling interest | 29 | 100 | -4 | 33 |
| Net loss attributable to lineage | -29,781 | -30,464 | -4,139 | -3,034 |
| Basic net loss per share | -0.13 | -0.13 | -0.02 | -0.02 |
| Diluted net loss per share | -0.13 | -0.13 | -0.02 | -0.02 |
| Weighted average number of shares outstanding, basic, total | 228,853,000 | 228,356,000 | 226,054,000 | 188,835,000 |
| Weighted average number of shares outstanding, diluted | 228,853,000 | 228,356,000 | 226,054,000 | 188,835,000 |
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)